Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis, Penn In Immunotherapy Pact

by Lisa M. Jarvis
August 13, 2012 | A version of this story appeared in Volume 90, Issue 33

Novartis has teamed with the University of Pennsylvania to bring chimeric antigen receptor (CAR) immunotherapies for the treatment of cancer to market. Penn’s CAR technology recodes a patient’s own T cells to express proteins found on the patient’s tumor. When reintroduced into the patient’s bloodstream, those engineered T cells can bind to and kill tumor cells. Novartis gains access to CART-19, an immunotherapy that has shown promise in a pilot study of patients with advanced chronic lymphocytic leukemia. The partners will build the Center for Advanced Cellular Therapies on the Penn campus in Philadelphia, where they plan to discover, develop, and manufacture adoptive T-cell immunotherapies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.